Curi RMB Capital LLC Invests $903,000 in Vaxcyte, Inc. (NASDAQ:PCVX)

Curi RMB Capital LLC bought a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 7,901 shares of the company’s stock, valued at approximately $903,000.

A number of other hedge funds have also recently bought and sold shares of PCVX. Darwin Global Management Ltd. boosted its position in Vaxcyte by 374.3% during the first quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock worth $187,907,000 after acquiring an additional 2,170,845 shares during the last quarter. Vanguard Group Inc. boosted its position in Vaxcyte by 15.2% during the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after acquiring an additional 1,284,883 shares during the last quarter. Capital Research Global Investors boosted its position in Vaxcyte by 20.4% during the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after acquiring an additional 700,414 shares during the last quarter. Janus Henderson Group PLC boosted its position in Vaxcyte by 9.9% during the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock worth $524,117,000 after acquiring an additional 692,492 shares during the last quarter. Finally, Avoro Capital Advisors LLC acquired a new stake in Vaxcyte during the first quarter worth approximately $39,278,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Trading Down 6.3 %

NASDAQ:PCVX opened at $86.83 on Friday. The firm has a market capitalization of $10.82 billion, a price-to-earnings ratio of -18.88 and a beta of 1.01. The firm’s fifty day simple moving average is $110.67 and its 200 day simple moving average is $88.46. Vaxcyte, Inc. has a twelve month low of $48.24 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter in the previous year, the company posted ($0.91) EPS. On average, analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Mikhail Eydelman sold 5,000 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $109.27, for a total value of $546,350.00. Following the completion of the sale, the senior vice president now owns 28,623 shares of the company’s stock, valued at approximately $3,127,635.21. The trade was a 14.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the completion of the sale, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at $37,822,574.24. The trade was a 3.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 117,464 shares of company stock valued at $12,640,276 in the last quarter. Company insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Bank of America lifted their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Mizuho lifted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Leerink Partners lifted their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Finally, Jefferies Financial Group lifted their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte has a consensus rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.